Histone deacetylase 4 inhibits NF-κB activation by facilitating IκBα sumoylation. (4th February 2021)

• Record Type: Journal Article
• Authors: Yang, Qi; Tang, Jielin; Xu, Chonghui; Zhao, He; Zhou, Yuan; Wang, Yanyi; Yang, Min; Chen, Xinwen; Chen, Jizheng
• Editors: Su, Bing
• Is Part Of: Journal of molecular cell biology. Volume 12:Number 12(2020)
• Page Start: 933
• Page End: 945
• Publication Date: 2021-02-04
• Subjects: histone deacetylase 4 -- sumoylation -- IκBα -- NF-κB -- SUMO E3 ligase; Molecular biology -- Periodicals; 571.605
• DOI: 10.1093/jmcb/mjaa043
• Languages: English
• ISSNs: 1674-2788

Abstract

Abstract: Protein modification by small ubiquitin-like modifier (SUMO) is an important regulatory mechanism for multiple cellular processes. Although the canonical pathway involving the ubiquitylation or phosphorylation of IκBα has been well characterized, little is known about the sumoylation of IκBα in the control of NF-κB activity. Here, we find that histone deacetylase 4 (HDAC4) negatively regulates tumor necrosis factor-alpha- or lipopolysaccharide-triggered NF-κB activation. HDAC4 belongs to the SUMO E3 ligase family and can directly sumoylate IκBα. The cytoplasm location of HDAC4 is essential for IκBα sumoylation. The Cys292 of HDAC4 is a key site for its SUMO E3 ligase activity. The sumoylation of IκBα prevents its polyubiquitination and degradation because these two modifications occur both at the Lys21. Our findings reveal a previously undiscovered role for HDAC4 in the inflammatory response as a SUMO E3 ligase for IκBα sumoylation. Our work provides insight into mechanisms ensuring optimal mediation of the NF-κB pathway.